Open AccessNOTTO COVID-19 vaccine guidelines for transplant recipients
Author(s) -
Vivek Kute,
Sanjay Kumar Agarwal,
Jai Prakash,
Sandeep Guleria,
Sunil Shroff,
Ashish Sharma,
Prem P Varma,
Narayan Prasad,
Manisha Sahay,
Subhash Gupta,
S Sudhindran,
Kewal Krishan,
Vasanthi Ramesh,
Sunil Kumar
Publication year - 2021
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_64_21
Subject(s) - medicine , herd immunity , pandemic , covid-19 , transmission (telecommunications) , population , immunology , disease , vaccination , vaccine failure , immunity , intensive care medicine , virology , immune system , infectious disease (medical specialty) , environmental health , measles , electrical engineering , engineering
In December 2019, novel coronavirus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within a few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID-19 vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID-19 infection or at least diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno-compromised patients should not receive live vaccines as they can cause vaccine-related disease and hence the guidelines suggest that all transplant recipients should receive age-appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population.